Intranasal Treatment of HIV-associated Neurocognitive Disorders
NCT ID: NCT03277222
Last Updated: 2020-06-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
4 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-11-01
Study Completion Date
2019-04-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to see whether intranasal insulin is an effective treatment for problems with memory, concentration, slowed thinking, or any other cognitive function in people living with HIV/AIDS. This group of signs and symptoms are called 'HIV-associated neurocognitive disorders' or HAND. HAND can affect people living with HIV/AIDS even when they receive potent anti-HIV treatments. Treatment of HAND by specific medication or other means is not yet available. Intranasal insulin treatment has virtually no side-effects, and has already been tested in people with Alzheimer's disease, where it showed beneficial effects on memory, mood and quality of life
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individualized Cognitive Training in HIV
NCT03122288
HIV-Associated Cognitive Motor Complex
Aging
Cognitive Impairment
+5 more
COMPLETED
NA
Liraglutide for HIV-associated Neurocognitive Disorder
NCT02743598
HIV Infection
Diabetes Mellitus Type 2
Obesity
+2 more
TERMINATED
PHASE4
Thinking and Memory Problems in People With HIV
NCT01875588
HIV Positive
RECRUITING
Effect of Cenicriviroc on HIV Neurocognitive Impairment
NCT02128828
AIDS Dementia Complex
HIV-1-Associated Cognitive Motor Complex
Human Immunodeficiency Virus
COMPLETED
PHASE2
Observational Study of HIV-associated Neurocognitive Disorder
NCT01966094
HIV Associated Neurocognitive Disorder
Human Immunodeficiency Virus
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is designed as a prospective, double-blinded pilot study of intranasal (IN) insulin versus placebo in people with HAND (n = 20) on stable ART medication. Participants will be randomly assigned to one of two groups: 40 IU IN insulin R twice daily, or matched-volume placebo, which will be administered twice daily, taken after breakfast and again after dinner using a nasal delivery device. Serum glucose will be tested for hypoglycemia one hour after the initial administration of IN insulin or placebo and after administration at Weeks 1, 2, and 3. If the dose is tolerated and no side effects are reported the participant will continue in the study. If the dose is not tolerated due to hypoglycemia then the participant will be withdrawn from the study.
The objectives of this study are as follows:
Primary: Determine if IN insulin treatment administered twice daily for 4 months reduces overall neurocognitive deficits (based on the global z-score in people with HAND).
Secondary: Measure effects of IN insulin on individual neuropsychological domains (e.g., memory, processing speed, executive functions, motor functions) and on HAND disease progression; Define impacts of IN insulin on quality of life and mood in people with HAND; Investigate IN insulin's effects on HAND biomarker profiles in urine and blood.
The objectives of this study are as follows:
Primary: Determine if IN insulin treatment administered twice daily for 4 months reduces overall neurocognitive deficits (based on the global z-score in people with HAND).
Secondary: Measure effects of IN insulin on individual neuropsychological domains (e.g., memory, processing speed, executive functions, motor functions) and on HAND disease progression; Define impacts of IN insulin on quality of life and mood in people with HAND; Investigate IN insulin's effects on HAND biomarker profiles in urine and blood.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV Associated Neurocognitive Disorder (HAND)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Arm 1: Drug: IN insulin Dose: Twice daily IN insulin R at 40 IU (n=10) twice daily using a nasal delivery device. IN insulin R will be administered twice daily.
Arm 2: Drug: Sterile Saline placebo Dose: Placebo (Sterile Saline placebo, matched volume; (n=10) twice daily using nasal delivery device.
Arm 2: Drug: Sterile Saline placebo Dose: Placebo (Sterile Saline placebo, matched volume; (n=10) twice daily using nasal delivery device.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
This is a prospective dose-ranging double-blinded pilot study over 4 months. At enrolment, participants and their physicians will be blinded to treatment.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IN insulin 40 IU
Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
Group Type
ACTIVE_COMPARATOR
IN insulin
Intervention Type
BIOLOGICAL
IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
IN Sterile Saline
Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
Group Type
PLACEBO_COMPARATOR
Sterile Saline placebo
Intervention Type
BIOLOGICAL
Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IN insulin
IN insulin twice daily taken after breakfast and again after dinner using the nasal delivery device.
Intervention Type
BIOLOGICAL
Sterile Saline placebo
Sterile Saline placebo twice daily taken after breakfast and again after dinner using the nasal delivery device.
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Intranasal Humulin R
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented HIV-1 infection
* Maintained on stable ART for ≥6 months (defined as undetectable viral load)
* HAND-MND or -ANI diagnosis with evidence of clinical onset or progression within the prior 2 years, based on established criteria
* Currently followed at the Southern Alberta Clinic (SAC; Calgary, AB, Canada)
* Maintained on stable ART for ≥6 months (defined as undetectable viral load)
* HAND-MND or -ANI diagnosis with evidence of clinical onset or progression within the prior 2 years, based on established criteria
* Currently followed at the Southern Alberta Clinic (SAC; Calgary, AB, Canada)
Exclusion Criteria
* HAND with a) changed dose of any medication for HIV-1 infection with a corresponding increase in viral load (e.g., ART), or b) secondary therapies for HAND (e.g., memantine, amphetamines).
* Advanced liver, renal or lung disease, cancer or diabetes requiring insulin
* Secondary diagnosis of neurocognitive impairment or other major neuropsychiatric illness such as epilepsy, Alzheimer's or Parkinson's diseases, major depression (PHQ-9 score \>10), or schizophrenia
* Central nervous system lesion (diagnosed by neuroimaging) that may impair cognition
* Previous allergic reaction to insulin or any of the carrier components.
* Education \< 9 years or inability to read and write English fluently
* Uncontrolled HIV-1 or hepatitis C co-infection
* Inability to perform NP or questionnaire measures, functional illiteracy
* Past or current substance abuse that could interfere with the study assessments as determined by the PI
* Marijuana use on the day of NP testing
* Uncontrolled cardiovascular disease (hypertension, coronary or peripheral artery disease)
* Advanced liver, renal or lung disease, cancer or diabetes requiring insulin
* Secondary diagnosis of neurocognitive impairment or other major neuropsychiatric illness such as epilepsy, Alzheimer's or Parkinson's diseases, major depression (PHQ-9 score \>10), or schizophrenia
* Central nervous system lesion (diagnosed by neuroimaging) that may impair cognition
* Previous allergic reaction to insulin or any of the carrier components.
* Education \< 9 years or inability to read and write English fluently
* Uncontrolled HIV-1 or hepatitis C co-infection
* Inability to perform NP or questionnaire measures, functional illiteracy
* Past or current substance abuse that could interfere with the study assessments as determined by the PI
* Marijuana use on the day of NP testing
* Uncontrolled cardiovascular disease (hypertension, coronary or peripheral artery disease)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Sponsor Role
collaborator
University of Alberta
OTHER
Sponsor Role
collaborator
Epidemiology Coordinating and Research Centre, Canada
OTHER
Sponsor Role
collaborator
University of Calgary
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Gill
Medical Director, Southern Alberta Clinic
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Power, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Michael J Gill, MBChB FACP
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Alberta Clinic
Calgary, Alberta, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789-99. doi: 10.1212/01.WNL.0000287431.88658.8b. Epub 2007 Oct 3.
Reference Type
BACKGROUND
Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005 May;32(2):201-4. doi: 10.1017/s0317167100003978.
Reference Type
BACKGROUND
Yeung H, Krentz HB, Gill MJ, Power C. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. AIDS. 2006 Oct 24;20(16):2005-9. doi: 10.1097/01.aids.0000247565.80633.d2.
Reference Type
BACKGROUND
Vivithanaporn P, Heo G, Gamble J, Krentz HB, Hoke A, Gill MJ, Power C. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010 Sep 28;75(13):1150-8. doi: 10.1212/WNL.0b013e3181f4d5bb. Epub 2010 Aug 25.
Reference Type
BACKGROUND
Mamik MK, Asahchop EL, Chan WF, Zhu Y, Branton WG, McKenzie BA, Cohen EA, Power C. Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. J Neurosci. 2016 Oct 12;36(41):10683-10695. doi: 10.1523/JNEUROSCI.1287-16.2016.
Reference Type
BACKGROUND
Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin. 2008 Aug;26(3):799-819, x. doi: 10.1016/j.ncl.2008.04.002.
Reference Type
BACKGROUND
Fujiwara, E., Gill, J.M. & Power, C. Risk Factors for HIV-Associated Neurocognitive Disorders (HAND) in a Canadian Cohort (P1.321). Neurology 86 P1.321 (2016).
Reference Type
BACKGROUND
McCombe JA, Vivithanaporn P, Gill MJ, Power C. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med. 2013 Feb;14(2):99-107. doi: 10.1111/j.1468-1293.2012.01043.x. Epub 2012 Sep 20.
Reference Type
BACKGROUND
Grant I, Franklin DR Jr, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK; CHARTER Group. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 Jun 10;82(23):2055-62. doi: 10.1212/WNL.0000000000000492. Epub 2014 May 9.
Reference Type
BACKGROUND
Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragin A, Levine A, Miller E. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 2016 Jan 26;86(4):334-40. doi: 10.1212/WNL.0000000000002277. Epub 2015 Dec 30.
Reference Type
BACKGROUND
Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1.
Reference Type
BACKGROUND
Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.
Reference Type
BACKGROUND
Hyun E, Ramachandran R, Hollenberg MD, Vergnolle N. Mechanisms behind the anti-inflammatory actions of insulin. Crit Rev Immunol. 2011;31(4):307-40. doi: 10.1615/critrevimmunol.v31.i4.30.
Reference Type
BACKGROUND
Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004 Nov;29(10):1326-34. doi: 10.1016/j.psyneuen.2004.04.003.
Reference Type
BACKGROUND
Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233. Epub 2011 Sep 12.
Reference Type
BACKGROUND
Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, Frey WH 2nd, Hanson LR. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs. 2014 Dec;28(12):1185-9. doi: 10.1007/s40263-014-0214-y.
Reference Type
BACKGROUND
Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimers Dis. 2013;35(4):789-97. doi: 10.3233/JAD-122308.
Reference Type
BACKGROUND
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis. 2015;44(3):897-906. doi: 10.3233/JAD-141791.
Reference Type
BACKGROUND
Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008 Feb 5;70(6):440-8. doi: 10.1212/01.WNL.0000265401.62434.36. Epub 2007 Oct 17.
Reference Type
BACKGROUND
Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012 Feb;97(2):366-76. doi: 10.1210/jc.2011-1802. Epub 2011 Dec 7.
Reference Type
BACKGROUND
Asahchop EL, Akinwumi SM, Branton WG, Fujiwara E, Gill MJ, Power C. Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. AIDS. 2016 Aug 24;30(13):2021-31. doi: 10.1097/QAD.0000000000001160.
Reference Type
BACKGROUND
Lenart N, Brough D, Denes A. Inflammasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab. 2016 Oct;36(10):1668-1685. doi: 10.1177/0271678X16662043. Epub 2016 Aug 2.
Reference Type
BACKGROUND
Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci. 2014 Feb;15(2):84-97. doi: 10.1038/nrn3638. Epub 2014 Jan 8.
Reference Type
BACKGROUND
Kim DH, Jewison DL, Milner GR, Rourke SB, Gill MJ, Power C. Neurocognitive symptoms and impairment in an HIV community clinic. Can J Neurol Sci. 2001 Aug;28(3):228-31. doi: 10.1017/s0317167100001372.
Reference Type
BACKGROUND
Koenig N, Fujiwara E, Gill MJ, Power C. Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. Can J Neurol Sci. 2016 Jan;43(1):157-62. doi: 10.1017/cjn.2015.306. Epub 2015 Dec 4.
Reference Type
BACKGROUND
Fujiwara E, Tomlinson SE, Purdon SE, Gill MJ, Power C. Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). J Clin Exp Neuropsychol. 2015;37(7):733-50. doi: 10.1080/13803395.2015.1057481. Epub 2015 Jul 24.
Reference Type
BACKGROUND
Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, Madenwald T, Becker JT, Conigliaro J, Brown ST, Rimland D, Crystal S, Simberkoff M; Veterans Aging Cohort 5-Site Study Project Team. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004 Jan 1;18 Suppl 1:S49-59.
Reference Type
BACKGROUND
Crane HM, Van Rompaey SE, Dillingham PW, Herman E, Diehr P, Kitahata MM. A single-item measure of health-related quality-of-life for HIV-infected patients in routine clinical care. AIDS Patient Care STDS. 2006 Mar;20(3):161-74. doi: 10.1089/apc.2006.20.161.
Reference Type
BACKGROUND
Power C, Gill MJ, Johnson RT. Progress in clinical neurosciences: The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neurol Sci. 2002 Feb;29(1):19-32. doi: 10.1017/s0317167100001682.
Reference Type
BACKGROUND
Van Marle G, Rourke SB, Zhang K, Silva C, Ethier J, Gill MJ, Power C. HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. AIDS. 2002 Sep 27;16(14):1905-14. doi: 10.1097/00002030-200209270-00007.
Reference Type
BACKGROUND
Skinner S, Adewale AJ, DeBlock L, Gill MJ, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009 Apr;10(4):246-52. doi: 10.1111/j.1468-1293.2008.00679.x. Epub 2009 Jan 23.
Reference Type
BACKGROUND
McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, Power C. Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology. 2009 Mar 3;72(9):835-41. doi: 10.1212/01.wnl.0000343854.80344.69.
Reference Type
BACKGROUND
Sacktor, N., et al. Paroxetine and Fluconazole Therapy for HAND: A Double-Blind, Placebo-Controlled Trial. Conference on retroviruses and opportunistic infections. 2016 Boston MA USA Sesssion O-12 Abstract 146(2016).
Reference Type
BACKGROUND
Power C, Boisse L, Rourke S, Gill MJ. NeuroAIDS: an evolving epidemic. Can J Neurol Sci. 2009 May;36(3):285-95. doi: 10.1017/s0317167100007009.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.ualberta.ca/department-of-medicine/powerlab
The Brain Power Lab
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Control# 204512
Identifier Type: OTHER
Identifier Source: secondary_id
REB17-0104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Decreased Mental Function Associated With HIV
NCT00027040
COMPLETED
NA
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
NCT00000392
COMPLETED
PHASE2
Efficacy of Neuro-HAART in Patients With HIV
NCT01434654
TERMINATED
Mental Ability Challenge Study in Adults With and Without HIV
NCT03244488
COMPLETED
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
NCT01600170
COMPLETED
PHASE4
The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
NCT07226128
NOT_YET_RECRUITING
NA
The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
NCT01434563
COMPLETED
Action for Brain Health Now: Ready, Set, Go
NCT04345484
UNKNOWN
NA
Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection
NCT02527460
TERMINATED
PHASE1
A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175
NCT00096824
COMPLETED
Effects of Anti-HIV Therapy on Nervous System Function
NCT00432003
COMPLETED
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
NCT00002414
UNKNOWN
PHASE2
Prevalence of HIV-associated Neurocognitive Disorders (HAND) in a School of Medicine HIV/AIDS Outpatient Clinic
NCT02187796
COMPLETED
Effects of Diet on Brain Processing
NCT02835820
COMPLETED
NA
PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection
NCT03239899
COMPLETED
PHASE1
Functional Imaging Reserve in NeuroHIV
NCT03596268
COMPLETED
A Novel Neurorehabilitation Approach for Cognitive Aging With HIV
NCT02391311
COMPLETED
NA
Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study
NCT02592174
COMPLETED
NA
Exploring Racial Disparities in Sleep Health and Neurocognitive Function
NCT04015830
COMPLETED
NA
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
NCT03268109
COMPLETED
Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy
NCT00002209
COMPLETED
PHASE1
Clinical Trial of CNS-targeted HAART (CIT2)
NCT00624195
COMPLETED
PHASE2/PHASE3
HIV-1 Infected Adult Subjects With HIV-associated Neurocognitive Disorders Despite Effective Antiretroviral Therapy
NCT04266002
COMPLETED
NA
The Targeted Neurocognitive Training (TNT) Study
NCT05773430
SUSPENDED
NA
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
NCT00540137
COMPLETED
PHASE4